Soluble E‐selectin, other markers of inflammation and disease severity in children with atopic dermatitis

Wolkerstorfer, Albert; Laan, M.P.; Savelkoul, H.F.J.; Neijens, H. J.; Mulder, Paul; Oudesluys‐Murphy, Anne Marie; Sukhai, R. N.; Oranje, Arnold P.

doi:10.1046/j.1365-2133.1998.02120.x

Cited by 51 publications

(35 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The plasma concentration of soluble E-selectin in children significantly correlated with disease activity, 17 whereas soluble P-selectin, soluble ICAM-1, and soluble VCAM-1 levels were unchanged. Soluble E-selectin appears to be the best serologic marker to determine disease activity in AD thus far.…”

Section: Selectinsmentioning

confidence: 79%

Role of vasculature in atopic dermatitis

Steinhoff

Steinhoff²,

Homey

et al. 2006

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Section: Selectinsmentioning

confidence: 79%

Role of vasculature in atopic dermatitis

Steinhoff

Steinhoff²,

Homey

et al. 2006

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

“…Next, the results were translated into arbitrary units (AU) by relating the obtained oxLDLÀLDL (OD) values of the test samples to the oxLDLÀLDL (OD) value of the reference in the same ELISA-plate. Levels of sICAM-1 were measured by capture ELISA (HBT, Uden, The Netherlands) using a monoclonal antibody to sICAM-1 (HM.2) as capture antibody and a biotin-labelled anti-ICAM-1 as detection antibody, as described elsewhere (Wolkerstorfer et al, 1998).…”

Section: A-linolenic Acid Atherosclerosis and Inflammation Wje Bemelmentioning

confidence: 99%

Increased α-linolenic acid intake lowers C-reactive protein, but has no effect on markers of atherosclerosis

et al. 2004

View full text Add to dashboard Cite

Objective: To investigate the effects of increased alpha-linolenic acid (ALA)-intake on intima-media thickness (IMT), oxidized low-density lipoprotein (LDL) antibodies, soluble intercellular adhesion molecule-1 (sICAM-1), C-reactive protein (CRP), and interleukins 6 and 10. Design: Randomized double-blind placebo-controlled trial. Subjects: Moderately hypercholesterolaemic men and women (55710 y) with two other cardiovascular risk factors (n ¼ 103). Intervention: Participants were assigned to a margarine enriched with ALA (fatty acid composition 46% LA, 15% ALA) or linoleic acid (LA) (58% LA, 0.3% ALA) for 2 y. Results: Dietary ALA intake was 2.3 en% among ALA users, and 0.4 en% among LA users. The 2-y progression rate of the mean carotid IMT (ALA and LA: þ 0.05 mm) and femoral IMT (ALA: þ 0.05 mm; LA: þ 0.04 mm) was similar, when adjusted for confounding variables. After 1 and 2 y, ALA users had a lower CRP level than LA users (net differences À0.53 and À0.56 mg/l, respectively, Po0.05). No significant effects were observed in oxidized LDL antibodies, and levels of sICAM-1, interleukins 6 and 10. Conclusions: A six-fold increased ALA intake lowers CRP, when compared to a control diet high in LA. The present study found no effects on markers for atherosclerosis. Sponsorship: The Dutch 'Praeventiefonds'.

show abstract

“…31 The index has shown agreement with global assessments of disease severity 35 as well as with various circulatory factors thought to reflect disease activity in atopic dermatitis. [32][33][34] However, problems with interobserver variation have occurred. In the original description of the scoring system, reliability was tested using 10 trained observers and 10 slides.…”

Section: The Scorad Indexmentioning

confidence: 99%

Outcome Measures of Disease Severity in Atopic Eczema

Charman

Williams²

2000

Arch Dermatol

180

218

View full text Add to dashboard Cite

Background: An essential component of evidencebased medicine is the use of valid and reliable outcome measures in clinical trials. There is much confusion in the field of atopic eczema regarding how to best measure disease severity objectively.Objective: To establish the extent to which existing objective clinical scales for atopic eczema have been tested for validity, reliability, sensitivity to change, and acceptability.Design: An electronic bibliographic search was performed for published data on all currently available named atopic eczema scales.Results: Thirteen scales were identified in total. Data on construct or criterion validity were available for 10 scales. Only 5 scales had been tested for reliability (interobserver variability, intraobserver variability, or internal consistency). Data on responsiveness to change were available for 8 scales. An estimated time to administer the measure had been given for 3 scales. The only severity scale for which published data could be found on validity, reliability, sensitivity, and acceptability testing was the Severity Scoring of Atopic Dermatitis index, although problems occurred with interobserver variation of the index. Conclusion:The rapidly increasing number of severity scales for atopic eczema, many of which have been inadequately tested, has made the interpretation of patient outcomes confusing, and comparison of results between studies almost impossible. Consensus among clinicians and researchers on the use of severity scales for atopic eczema should be based on evidence of adequate validity, reliability, sensitivity to change, and ease of use.

show abstract

Soluble E‐selectin, other markers of inflammation and disease severity in children with atopic dermatitis

Cited by 51 publications

References 22 publications

Role of vasculature in atopic dermatitis

Role of vasculature in atopic dermatitis

Increased α-linolenic acid intake lowers C-reactive protein, but has no effect on markers of atherosclerosis

Outcome Measures of Disease Severity in Atopic Eczema

Contact Info

Product

Resources

About